Related Experiment Video
Updated: Jul 7, 2026
08:05
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
Published on: May 19, 2021
Current utilization trends for beta-blockers in cardiovascular disease.
1Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
The American Journal of Medicine
|March 22, 2001
Summary
Beta blockers offer significant benefits for heart failure patients, yet their use remains low. Increased awareness and updated guidelines are crucial for improving patient outcomes and reducing mortality.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Beta blockers are recommended by treatment guidelines for various diseases.
- Despite recommendations, beta blocker utilization is notably low.
- Factors influencing prescribing patterns include marketing, legal concerns, and demographics.
Purpose of the Study:
- To highlight the discrepancy between recommended and actual beta blocker use.
- To emphasize the proven benefits of beta blockers in heart failure.
- To advocate for increased appropriate beta blocker therapy.
Main Methods:
- Review of existing treatment guidelines and clinical trial evidence.
- Analysis of factors affecting drug prescribing trends.
- Synthesis of data on beta blocker efficacy in heart failure.
Main Results:
- Randomized clinical trials show significant benefits of adding beta blockers to standard heart failure therapy.
- Low adherence to guidelines for beta blocker prescription is evident.
- Multiple factors contribute to the underutilization of beta blockers.
Conclusions:
- Beta blocker therapy significantly reduces mortality and morbidity in heart failure patients.
- Efforts are needed to improve the appropriate prescription of beta blockers.
- Updating therapeutic practices based on current evidence is essential for patient care.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...